Cargando…

Projected impact of Cervarix™ vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom

We developed a dynamic compartmental model to assess the impact of HPV Universal Mass Vaccination (UMV) with Cervarix™, which offers protection against HPV16/18 and cross-protection against other cancer-causing types, using up-to-date efficacy data. Analyses were performed in the UK because of the l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Effelterre, Thierry P, Hogea, Cosmina, Taylor, Sylvia M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155626/ https://www.ncbi.nlm.nih.gov/pubmed/26090944 http://dx.doi.org/10.1080/21645515.2015.1054584

Ejemplares similares

Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement
por: Hogea, Cosmina, et al.
Publicado: (2015)

A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection
por: Hogea, Cosmina, et al.
Publicado: (2015)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

A model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?
por: Hogea, Cosmina, et al.
Publicado: (2014)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis
por: Haghshenas, Mohammad Reza, et al.
Publicado: (2017)

A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix(®) and Gardasil(®) Human Papillomavirus Vaccines in 12-15 Year Old Girls
por: Draper, Eve, et al.
Publicado: (2013)

Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()
por: Bissett, Sara L., et al.
Publicado: (2014)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Economic evaluation of human papillomavirus vaccination in the United Kingdom
por: Jit, Mark, et al.
Publicado: (2008)

Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study
por: Mehanna, Hisham, et al.
Publicado: (2019)

Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination
por: Pimenta, Jeanne M, et al.
Publicado: (2013)

Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States
por: Talbird, Sandra E, et al.
Publicado: (2020)

87. Impact of State of Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach
por: Hunter, Shannon, et al.
Publicado: (2020)

2726. Meningococcal Vaccination Among Patients Newly Diagnosed at High-Risk for Meningococcal Disease in the United States
por: Bengtson, Lindsay, et al.
Publicado: (2019)

A basic dynamic transmission model of Staphylococcus aureus in the US population
por: HOGEA, C., et al.
Publicado: (2014)

Improving physical health for psychiatric patients detained in a low secure forensic psychiatric unit in the United Kingdom
por: Cross, Cosmina
Publicado: (2021)

A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand
por: Jiamsiri, Suchada, et al.
Publicado: (2022)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?
por: Curran, Desmond, et al.
Publicado: (2016)

2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?
por: Cheng, Wendy, et al.
Publicado: (2018)

962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016
por: Gargano, Julia, et al.
Publicado: (2019)

Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer
por: Faridi, Rabia, et al.
Publicado: (2011)

Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2011)

Oncogenic human papillomaviruses
por: McBride, Alison A.
Publicado: (2017)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States
por: Marshall, Gary S, et al.
Publicado: (2021)

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination
por: Goldhaber-Fiebert, Jeremy D, et al.
Publicado: (2007)

Nucleolin as Activator of Human Papillomavirus Type 18 Oncogene Transcription in Cervical Cancer
por: Grinstein, Edgar, et al.
Publicado: (2002)

Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand
por: Simonella, Leonardo M, et al.
Publicado: (2013)

State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling Approach
por: Garbinsky, Diana, et al.
Publicado: (2021)

Cancer mortality in the United Kingdom: projections to the year 2025
por: Olsen, A H, et al.
Publicado: (2008)

Cancer incidence in the United Kingdom: projections to the year 2030
por: Mistry, M, et al.
Publicado: (2011)

Projections of cancer prevalence in the United Kingdom, 2010–2040
por: Maddams, J, et al.
Publicado: (2012)

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom
por: Pritchard, Emma, et al.
Publicado: (2021)

1414. #Vaccine Twitter Influencers: is it Just About Reach and Followers?
por: Poirrier, Jean-Etienne, et al.
Publicado: (2020)

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach
por: Pan-Ngum, Wirichada, et al.
Publicado: (2017)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

Twin Peaks: A/H1N1 Pandemic Influenza Virus Infection and Vaccination in Norway, 2009–2010
por: Van Effelterre, Thierry, et al.
Publicado: (2016)

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
por: Abogunrin, Seye, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8mj6eseqg9sng612n9f5qph879